Alec Stranahan
Stock Analyst at B of A Securities
(0.67)
# 4,099
Out of 5,129 analysts
33
Total ratings
38.46%
Success rate
-46.15%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alec Stranahan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KRYS Krystal Biotech | Maintains: Buy | $288 → $318 | $270.70 | +17.47% | 6 | Jan 22, 2026 | |
| CADL Candel Therapeutics | Downgrades: Neutral | $13 → $7 | $5.76 | +21.53% | 2 | Sep 3, 2025 | |
| XNCR Xencor | Downgrades: Neutral | $23 → $12 | $12.37 | -2.99% | 2 | Sep 3, 2025 | |
| ERAS Erasca | Downgrades: Underperform | $4 → $1 | $11.95 | -91.63% | 3 | Sep 3, 2025 | |
| NVAX Novavax | Downgrades: Underperform | $9 → $7 | $8.75 | -20.00% | 5 | Aug 20, 2025 | |
| BEAM Beam Therapeutics | Upgrades: Buy | $42 | $26.95 | +55.84% | 1 | Mar 28, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Buy | $28 → $25 | $11.42 | +118.91% | 5 | Jan 7, 2025 | |
| CRBU Caribou Biosciences | Maintains: Buy | $13 → $11 | $1.57 | +600.64% | 1 | Jan 7, 2025 | |
| CATX Perspective Therapeutics | Downgrades: Neutral | $24 → $6 | $4.74 | +26.58% | 2 | Nov 25, 2024 | |
| EDIT Editas Medicine | Upgrades: Buy | $13 → $15 | $1.78 | +742.70% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $55 | $95.98 | -42.70% | 3 | Jul 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $5 → $6 | $29.14 | -79.41% | 2 | Dec 29, 2022 |
Krystal Biotech
Jan 22, 2026
Maintains: Buy
Price Target: $288 → $318
Current: $270.70
Upside: +17.47%
Candel Therapeutics
Sep 3, 2025
Downgrades: Neutral
Price Target: $13 → $7
Current: $5.76
Upside: +21.53%
Xencor
Sep 3, 2025
Downgrades: Neutral
Price Target: $23 → $12
Current: $12.37
Upside: -2.99%
Erasca
Sep 3, 2025
Downgrades: Underperform
Price Target: $4 → $1
Current: $11.95
Upside: -91.63%
Novavax
Aug 20, 2025
Downgrades: Underperform
Price Target: $9 → $7
Current: $8.75
Upside: -20.00%
Beam Therapeutics
Mar 28, 2025
Upgrades: Buy
Price Target: $42
Current: $26.95
Upside: +55.84%
Day One Biopharmaceuticals
Jan 7, 2025
Maintains: Buy
Price Target: $28 → $25
Current: $11.42
Upside: +118.91%
Caribou Biosciences
Jan 7, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $1.57
Upside: +600.64%
Perspective Therapeutics
Nov 25, 2024
Downgrades: Neutral
Price Target: $24 → $6
Current: $4.74
Upside: +26.58%
Editas Medicine
Aug 8, 2024
Upgrades: Buy
Price Target: $13 → $15
Current: $1.78
Upside: +742.70%
Jul 16, 2024
Maintains: Buy
Price Target: $48 → $55
Current: $95.98
Upside: -42.70%
Dec 29, 2022
Maintains: Underperform
Price Target: $5 → $6
Current: $29.14
Upside: -79.41%